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ABSTRACT
Endometrial cancer (EC) is the sixth deadliest cancer in women. The depth of 
myometrial invasion is one of the most important prognostic factors, being directly 
associated with tumor recurrence and mortality. In this study, ALCAM, a previously 
described marker of EC recurrence, was studied by immunohistochemistry at the 
superficial and the invasive tumor areas from 116 EC patients with different degree 
of myometrial invasion and related to a set of relevant epithelial and mesenchymal 
markers. ALCAM expression presented a heterogeneous functionality depending on 
its localization, it correlated with epithelial markers (E-cadherin/β-catenin) at the 
superficial area, and with mesenchymal markers at the invasive front (COX-2, SNAIL, 
ETV5, and MMP-9). At the invasive front, ALCAM-negativity was an independent marker 
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of myometrial invasion. This negativity, together with an increase of soluble ALCAM in 
uterine aspirates from patients with an invasive EC, and its positive correlation with 
MMP-9 levels, suggested that ALCAM shedding by MMP-9 occurs at the invasive front. 
In vivo and in vitro models of invasive EC were generated by ETV5-overexpression. In 
those, we demonstrated that ALCAM shedding was related to a more invasive pattern 
and that full-ALCAM recovery reverted most of the ETV5-cells mesenchymal abilities, 
partially through a p-ERK dependent-manner.
INTRODUCTION
Endometrial cancer (EC) is the most common 
gynecologic cancer and the sixth most deathly cancer 
in women from western countries [1]. Myometrial 
invasion is one of the most important prognostic 
factors of EC and represents an increase in the rate of 
recurrence and a decrease in the 5-year survival [2]. The 
first step of myometrial invasion is characterized by the 
dissociation of tumor cells from the epithelial layer of 
the endometrial glands, and their subsequent infiltration 
through the basement membrane into the adjacent layer, 
the myometrium [3]. For that to happen, several authors 
suggest that epithelial tumor cells need to undergo an 
epithelial-to-mesenchymal transition (EMT). Moreover, 
it is known that in invading tumors this process takes 
place at the invasive front [4–6]. EMT is a dynamic 
process controlled by external signals coming from the 
tumor cells microenvironment, that involves cellular loss 
of polarity, loosen cell-cell contacts, reorganization of 
cytoskeleton and acquisition of plasticity, motility and 
invasive capabilities. Multiple factors have been described 
as being responsible for producing EMT in EC, such as 
ETV5, estrogen and progesterone receptors, and TGF-β, 
among others [3].
Activated-leukocyte cell adhesion molecule 
(ALCAM) is a cell-cell adhesion molecule of 105-kDa from 
the immunoglobulin superfamily (IgSF) that participates 
either in homotypic (ALCAM-ALCAM) or heterotypic 
(ALCAM-CD6) interactions between adjacent cells [7]. 
ALCAM presents 5 extracellular immunoglobulin domains 
(D1–D5), comprising 2 NH2-terminal, membrane-distal 
variable-(V)-type and 3 membrane-proximal constant-(C2)-
type Ig folds, a transmembrane-region and a short carboxy-
terminal cytoplasmic tail. The extracellular domains 
provide two structural and functional modules, responsible 
for ligand affinity (D1-D2) that mediates receptor trans-
trans-interactions between opposing cells, and avidity 
(D3-D5). The strength of the avidity is controlled by 
recruitment of ALCAM molecules to the site of cell-cell 
contact and by receptor cis-oligomerization via the C-type 
immunoglobulin domains. Coordination of both modules is 
necessary for stable ALCAM-ALCAM interaction, leading 
to the formation of a tight bilayered ALCAM network [8]. 
Both, homotypic and heterotypic interactions are mediated 
through its amino-terminal V domain (D1). ALCAM-
ALCAM interactions are described as a D1–D1 interaction, 
while in ALCAM–CD6 interactions the ALCAM D1 
domain binds to the CD6 membrane-proximal scavenger 
receptor cysteine rich (SRCR) domain [9, 10].
Activation of ALCAM-mediated adhesion is 
dynamically regulated through actin cytoskeleton-
dependent clustering. Zimmerman et al. described the 
interaction between ALCAM and the actin cytoskeleton 
[11]. This interaction could be allowed by the presence in 
its short cytoplasmic tail of a positive-charge-rich domain 
(PCRD) as well as a PDZ-binding motif KTEA placed at 
the C-terminus [12]. The inhibition of actin polymerization 
by low levels of cytochalasin D stimulates homotypic 
ALCAM–ALCAM interactions, increases protein lateral 
mobility, and the formation of ALCAM clusters in the 
cell surface, demonstrating that cytoskeleton regulates 
ALCAM-mediated adhesion [13]. Moreover, ALCAM has 
been observed to form a supra-molecular complex with 
Syntenin-1 and Ezrin [14]. PKCα also plays a role in the 
cytoskeleton-dependent avidity modulation of ALCAM 
and regulates the supra-molecular complex formed by 
ALCAM-Ezrin [15].
ALCAM expression in the cell surface can 
be regulated by endocytosis or protein cleavage. In 
fact, ALCAM co-localizes with clathrin in a process 
that is regulated by ubiquitination and dependent on 
ERK phosphorylation [16, 17]. ALCAM levels can 
be also regulated by protein shedding via ADAM-17 
metalloproteinase [18], generating a soluble 96-kDa 
form and a truncated membrane-bound. ALCAM is 
widely distributed within tissues and its function has 
been reported in extensive biological processes [19]. In 
the last years, it has been associated to the tumorigenesis 
of many cancers [20–27]. However, ALCAM expression 
and localization within the tumor cell have generated 
great controversy, and its relation to prognosis remain 
still unclear [28]. In addition, ALCAM shedding has 
been reported in the serum of breast, ovarian, thyroid and 
pancreatic cancer patients and in all the cases, related to 
poor clinical outcome [24, 29–31]. We have previously 
demonstrated that ALCAM is an important player in 
endometrioid endometrial cancer (EEC) dissemination 
[32]. In fact, we described that ALCAM-positivity is a 
marker of recurrence in early stage EEC and promotes 
migration and invasion in vitro and in vivo.
In this study, we go further in our understanding 
of ALCAM in EC tumorigenesis by evaluating its full-
form expression in two different areas of the tumor and 
its relation with key molecules associated to the epithelial 
and mesenchymal context. Immunohistochemical staining 
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for ALCAM in tissues was conducted with an antibody 
directed against the extracellular domain of the protein. 
Since, ALCAM can be proteolytically processed by 
metalloproteinases, thereby generating a soluble ALCAM 
component and a truncated membrane-bound ALCAM 
containing the transmembrane and cytoplasmic domain, 
the antibody recognized the non-cleaved protein.
We found a switch in the functional mode of 
ALCAM in EEC. Whereas at the superficial area of the 
tumor ALCAM correlated with the E-Cadherin/β-Catenin 
adhesion complex, at the invasive front ALCAM could be 
shed by MMP-9 in poor prognosis scenarios. Moreover, 
we evaluated the shed ALCAM, or soluble form 
(sALCAM), in uterine aspirates as a potential diagnostic 
tool to predict myometrial invasion.
RESULTS
ALCAM expression presented a different 
correlation profile depending on its localization 
within the tumor
We studied the immunohistochemical expression of 
ALCAM extracellular domain (non-cleaved protein) and 
a representative set of epithelial (E-cadherin/β-catenin 
major adhesion complex) and mesenchymal molecules 
involved in EEC dissemination (ETV5, COX-2, SNAIL, 
SLUG, MMP-2 and -9), in both the superficial and the 
invasive areas of the tumor. As our previous results 
indicated a different behavior of ALCAM regarding tumor 
differentiation, analyses were performed in the entire 
population, and in the well-differentiated (GI) and poorly-
differentiated (GII-III) subcohorts [32].
Univariate regression analyses were performed 
as a first approach to evaluate the association between 
ALCAM and epithelial and mesenchymal markers. 
Variables that significantly correlated with ALCAM 
(Supplementary Table 1) were included in multivariate 
linear regression models. ALCAM presented a significant 
positive correlation with the major adhesion complex 
at the superficial area of the tumor. Whilst β-catenin 
was retained as an outcome variable in all patients and 
in the well-differentiated cohort (R=0.437 and 0.394, 
respectively), E-cadherin was retained in the moderately-
poorly differentiated tumors (R=0.445) (Supplementary 
Table 2, Figure 1A). By contrast, at the invasive front of 
the tumor, SNAIL, COX-2 and MMP-9 were retained as 
outcome variables of the model, in all patients. COX-2 and 
SNAIL were positively correlated with ALCAM, whilst 
MMP-9 was negatively correlated. The best regression 
adjustment was reached in the moderately-poorly 
differentiated subcohort of patients, in which the model 
retained ETV5 and MMP-9 (R=0.559). Both molecules 
showed a negative correlation with ALCAM. Altogether, 
the results suggested a different functional profile of 
ALCAM according to its tumor localization, i.e. whilst it 
correlated with epithelial markers at the superficial tumor, 
correlations with mesenchymal markers were observed at 
the invasive front.
ALCAM-negativity at the invasive front of the 
tumor is a marker of myometrial invasion
We further investigated the role of ALCAM at the 
different tumor areas. At the superficial area, ALCAM 
expression was unrelated to the clinical parameters of 
myometrial invasion, tumor grade, and tumor progression. 
However, it acted as a marker of tumor progression and 
invasion when analyzed at the invasive front. In this tumor 
area, ALCAM significantly decreased along tumor stages 
and in tumors with myometrial invasion >50% (Table 1, 
Figure 1B-1C). In fact, the potential of ALCAM-negativity 
as an independent prognostic factor of myometrial 
invasion was confirmed by multivariate logistic regression 
analysis with an OR 3.273, together with the tumor grade 
(OR 3.484) (Table 2).
ALCAM maintained a close and inverse relation 
with MMP-9 at the invasive front of the tumor (p=0.004; 
OR 0.26) (Table 3). This relation was only preserved 
in poor prognosis tumors when the cohort was divided 
according to clinical parameters, i.e. either in tumors 
with moderately-poorly differentiated EEC histology 
(p=0.02; OR 0.08), in patients presenting >50% of 
myometrial infiltration (p=0.016; OR 0.19), and in 
ETV5-positive tumors (p=0.009; OR 0.22). Altogether, 
our results demonstrated that ALCAM-negativity is a 
marker for myometrial invasion at the invasive front. Its 
close and inverse relation with MMP-9 in poor prognosis 
scenarios, led us speculate that ALCAM-negativity might 
be due to an increased shedding of the protein by the 
metalloproteinase at the invasive front of poor prognostic 
tumors.
ALCAM shedding takes place in tumors with 
myometrial invasion and correlates with MMP-9 
expression
In order to evaluate the possible association 
between ALCAM shedding and myometrial invasion, we 
analyzed the expression of soluble ALCAM (sALCAM) 
by ELISA, in 40 uterine aspirates from moderately-
poorly differentiated EEC patients with different depth 
of myometrial infiltration. The uterine aspirate is a 
bodyfluid that is collected from inside of the uterine 
cavity, and is mainly formed by the secretion of the tumor 
cells and other cells from the endometrium, enabling the 
detection of cleaved ALCAM produced by the tumor. We 
confirmed that sALCAM was significantly increased in 
patients presenting myometrial invasion >50% (Figure 
2A). Moreover, ROC analysis showed that sALCAM in 
uterine aspirates is a significant predictor of myometrial 
infiltration (AUC 0.8; p=0.001) (Figure 2B). In fact, when 
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ALCAM is set at a cut-off of 9.375 ng/mg, the model 
presents a sensitivity of 87% and a specificity of 70.6%.
Then, the relation between sALCAM and MMP-9 
was assessed in uterine aspirates by performing a gelatin 
zymography of the same patients (Figure 2C). Linear 
regression analyses (Supplementary Table 3) evidenced 
a significant positive correlation between sALCAM with 
all MMP-9 detected forms, with the exception of the 
more labile active form. No correlation was found with 
the MMP-2 forms (data not shown). In order to avoid the 
problems derived from the simultaneous use of several 
measurements that reflect expressions of molecular forms 
of the same enzyme (Supplementary Table 3), PCA was 
addressed to explore the close relationship among the four 
MMP-9 forms and reduce their number before performing 
regression analysis. Two main components C1, which 
explains 75.18% of the variability of the original dataset, 
and C2 which only explains 13.86%, were extracted 
(Figure 2D). Regression analyses showed a strong and 
positive correlation between sALCAM and C1, and 
specifically in patients presenting myometrial invasion 
>50% (R=0.575; p=0.004) (Figure 2E, 2F). These results 
suggested that at the invasive front of the tumor, ALCAM 
extracellular shedding by MMP-9 could be an important 
process in myometrial invasion.
ALCAM and MMP-9 are important actors at 
the invasive front of an in vivo model of EEC 
dissemination
The Hec1A-ETV5 overexpression model has been 
extensively used to mimic the process of tumor invasion in 
EEC [33–35], as ETV5 overexpression is known to induce 
EMT in EEC and has been reported at the invasive front 
of EEC tumors, promoting migration and invasion in vitro 
Figure 1: ALCAM expression presented a different correlation profile depending on its localization within the tumor 
and its decrease at the invasive front is a marker of myometrial invasion. (A) Upper: Full-length ALCAM was significantly and 
positively correlated with the E-cadherin/β-catenin complex at the superficial tumor and is mainly localized at the cell membrane. Down: At 
the invasive front, full-length ALCAM is significantly inversely correlated with MMP-9 and ETV5, in the moderately-poorly differentiated 
EEC. (B) ALCAM-negativity, at the invasive front, is a marker of myometrial invasion (C) At the invasive front, ALCAM-negative tumors 
increased from a 21.8% in patients without myometrial invasion to a 45.1% in patients presenting myometrial infiltration (p-value= 0.014).
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and in vivo. Furthermore, the parental Hec1A cell line is 
representative of moderately-poorly differentiated EEC 
tumor with epithelial-like morphology [33, 36]. To study 
ALCAM in a controlled environment, which represents a 
realistic approach towards the process of dissemination of 
EC, we generated orthotopic murine models with Hec1A 
(n=5) or its ETV5-overexpressing cells (n=4), directly 
injected into the uterus of the mice. In this model, tumor 
cells are localized in the same microenvironment of the 
original tumor, resembling the processes of tumor growth 
and myometrial infiltration under endometrial stimuli.
As expected, the tumors generated by the ETV5-
overexpressing cells presented larger myometrial invasion 
and tumor burden (Supplementary Figure 1A-1B). 
While in the ETV5-overexpressing tumors, we observed 
disseminated cells in finger-like strands or single-cells, 
projecting into the stroma at the invasive front; in the 
Hec1A tumors, cells invaded forming clusters (see arrows 
in Figure 3A), as previously observed by Muinelo-Romay 
et al. in vitro [37]. The immunohistochemical staining of 
uncleaved ALCAM, MMP-9, and ETV5 in the mice’s 
primary tumors unveiled that ALCAM expression is 
reduced at the invasive front of ETV5-overexpressing 
compared to Hec1A tumors (p<0.05; Figure 3B), and 
moreover, the pattern of expression is modified from a 
very membranous staining in Hec1A tumors to a diffuse 
cytoplasmic staining in ETV5-overexpressing cells 
(Figure 3A).
Table 1: ALCAM and clinical parameters
Variable, No. (%) Σ ALCAM Positive* ALCAM Negative† P-value
Superficial area of the tumor
FIGO 116 82 (70.7) 34 (29.3) 0.208
 IA 56 42 (75.0) 14 (25.0)
 IB 41 28 (68.3) 13 (31.7)
 II 15 11 (73.3) 4 (26.7)
 III 4 1 (25.0) 3 (75.0)
Grade 116 82 (70.7) 34 (29.3) 0.131
 Grade I 79 60 (75.9) 19 (24.1)
 Grade II 24 13 (54.2) 11 (45.8)
 Grade III 13 9 (69.2) 4 (30.8)
Myometrial infiltration 116 82 (70.7) 34 (29.3) 0.541
 < 50% 58 43 (74.1) 15 (25.9)
 ≥ 50% 58 39 (67.2) 19 (32.8)
Invasive front of the tumor
FIGO 106 71 (67.0) 35 (33.0) 0.004**
 IA 53 42 (79.2) 11 (20.8)
 IB 36 21 (58.3) 15 (41.7)
 II 13 8 (61.5) 5 (38.5)
 III 4 0 (0.0) 4 (100.0)
Grade 106 71 (67.0) 35 (33.0) 0.213
 Grade I 72 52 (72.2) 20 (27.8)
 Grade II 22 13 (59.1) 9 (40.9)
 Grade III 12 6 (50.0) 6 (50.0)
Myometrial infiltration 106 71 (67.0) 35 (33.0) 0.014*
 < 50% 55 43 (78.2) 12 (21.8)
 ≥ 50% 51 28 (54.9) 23 (45.1)
*Positive ≥ 65 †Negative < 65.
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Interestingly, the intensity of ALCAM and MMP-
9 showed no variation between the superficial or the 
invasive area in Hec1A tumors, but their intensity was 
altered in the ETV5-overexpressing tumors. In those, 
MMP-9 increased concomitant with a decrease in ALCAM 
from the superficial area to the invasive front of the tumor 
(Figure 3, Supplementary Figure 1C).
As a result of the in vivo model, we evidenced that 
the cell-cell contacts of the Hec1A invading cells seem to 
be preserved, as shown by the highly collective migration 
and a homogeneous ALCAM expression. However, the 
ETV5-overexpressing invading cells were more prone to 
present switching between thin cords and single-cells, both 
related to decreased or more transient contacts and higher 
rate of cleaved ALCAM expression. We finally confirmed 
that in an invasive scenario, ALCAM and MMP-9 are 
important actors at the invasive front of the tumor.
Recovery of ALCAM expression reduced the 
aggressiveness of invasive EEC cells
To understand the role of ALCAM at the 
invasive process, we recovered its expression in 
the invasive Hec1A-ETV5 model by using two 
ALCAM-overexpression vectors: one containing 
a full-length ALCAM (full-ALCAM) and another 
containing the extracellular and transmembrane regions 
(ALCAMcytoless), both cloned in pmCherry-N1 vectors 
(Figure 4A). When transiently transfected in Hec1A-
ETV5 cells, ALCAM-overexpression was localized 
predominantly in the plasma membrane (Figure 4B-4C). 
To evaluate the effects of ALCAM-recovery in ETV5-
overexpressing cells, we used 3D in vitro approaches 
that closely mimic the in vivo settings. We used a 
spheroid model to quantitatively study the spreading of 
cell aggregates on fibronectin-coated stripes. In addition 
to reproduce characteristics of the in vivo environment, 
this model allows us to analyze the competition between 
cell–cell and cell–substratum adhesion on tissue spreading 
[38]. In both conditions (ALCAM full-length and 
ALCAMcytoless) the speed was significantly decreased 
compared to the control cells (Figure 4D-4E). However, 
the larger difference was found in the full-length ALCAM-
transfected cells. In fact, we observed that the mean time of 
disaggregation of the Cherry-control spheroids was around 
5 h, while ALCAM full-length and ALCAMcytoless 
expressing aggregates needed approximately 21 h and 
18 h, respectively (Figure 4D). Moreover, the pattern 
of spreading in control cells presented a more spindle-
shaped phenotype, with larger presence of individual 
cells and protrusions, highly dynamic transient cell-cell 
contacts, migration in a sheet fashion and presentation 
of chemotactic abilities. In contrast, full-ALCAM and 
ALCAMcytoless cells presented an increased intercellular 
adhesion phenotype and a more collective pattern of 
spreading (Figure 4D, Supplementary Videos 1-3). 
Consequently, ALCAM recovery clearly impaired the 
migratory abilities of ETV5-overexpressing cells.
To verify these effects we evaluated how ALCAM-
rescue affects the formation and strength of cell-cell 
adhesion. We used two micropipettes to put into contact 
two isolated cells maintained in suspension, to avoid cell-
matrix interactions, and initiate adhesion. Single cells 
were chosen under a fluorescence microscope to verify 
the Cherry-transfection. The mean separation force (SF) is 
used as a read-out of the strength of adhesion for a precise 
contact time. In all the cases, the SF required to disrupt the 
cell doublet increased with the contact time. We observed 
that at 4 min both ALCAM-transfected cells presented 
significantly larger adhesion than the control line (Figure 
Table 2: Multivariate logistic regression model related to the myometrial invasion ≥50% (N = 89)
Variable OR 95% Interval confidence P-value
Grade
 Differentiated tumors (Grade I) 1
 Moderateley-poorly differentiated tumors (Grade II-III) 3.484 (1.284-9.524) 0.014*
ALCAM
 Positive 1
 Negative 3.273 (1.200-8.932) 0.021*
MMP-9
 Positive 1
 Negative 1.629 (0.602-4.409) 0.337
ETV5
 Positive 1
 Negative 0.556 (0.194-1.592) 0.274
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4F). Cells expressing full-length ALCAM displayed 
stronger intercellular adhesion, as shown by the two-fold 
increase in their SF compared to control cells, and were 
more adhesive than cells expressing ALCAMcytoless. 
In contrast, at 10 min only the full-length ALCAM-
transfected cells presented significantly stronger adhesion 
than the control. Thus, we showed that ALCAM shedding 
was important to reduce the adhesive properties of the 
cells. In this particular context, the cytoplasmic tail 
plays an important role in cell-cell adhesion formation or 
maturation.
The molecular pathway by which ETV5 promotes 
its invasive functions in EC has been recently postulated 
by Alonso-Alconada et al. [39]. The authors described 
how ETV5 works through the BDNF–TrkB–ERK1/2 
axis by inducing ERK1/2 phosphorylation, leading 
to the promotion of migration and invasion. In this 
work, we observed that ALCAM-overexpression was 
concomitant with a decrease in p-ERK, without reverting 
to an epithelial phenotype (Figure 4G), but impairing 
the migratory and increasing the adhesive properties 
promoted by ETV5. Although overexpression of the 
ALCAMcytoless is sufficient to reduce the levels of 
p-ERK and to decrease spheroid spreading, ALCAM full-
length is necessary to increase cell-cell adhesion with 
time.
Table 3: ALCAM and MMP-9 correlation at the invasive front of the tumor
Variable, No. (%) Σ ALCAM Positive* ALCAM Negative† P-value OR (Positive/Negative)
All 95 64 (67.4) 31 (32.6) 0.004** 0.26 (0.10-0.66)
 MMP-9 Positive 47 25 (53.2) 22 (46.8)
 MMP-9 Negative 48 39 (81.3) 9 (18.8)
Clinical parameters
Grade
 Differentiated tumors 64 46 (71.9) 18 (28.1) 0.162 N.S
 MMP-9 Positive 26 16 (61.5) 10 (38.5)
 MMP-9 Negative 38 30 (78.9) 8 (21.1)
Moderately- Poorly differentiated 
tumors 31 18 (58.1) 13 (41.9) 0.020
* 0.08 (0.03-0.63)
 MMP-9 Positive 21 9 (42.9) 12 (57.1)
 MMP-9 Negative 10 9 (90.0) 1 (10.00)
Myometrial infiltration <50% 53 41 (77.4) 12 (22.6) 0.190 N.S
 MMP-9 Positive 25 17 (68.0) 8 (32.0)
 MMP-9 Negative 28 24 (85.7) 4 (14.3)
Myometrial infiltration ≥50% 42 23 (54.8) 19 (45.2) 0.016* 0.19 (0.03-0.65)
 MMP-9 Positive 22 8 (36.4) 14 (63.6)
 MMP-9 Negative 20 15 (75.0) 5 (25.0)
Molecular features
ETV5 Positive 64 40 (62.5) 24 (37.5) 0.009** 0.22 (0.07-0.69)
 MMP-9 Positive 37 18 (48.6) 19 (51.4)
 MMP-9 Negative 27 22 (81.5) 5 (18.5)
ETV5 Negative 25 19 (76.0) 6 (24.0) 1.000 N.S
 MMP-9 Positive 7 5 (71.4) 2 (28.6)
 MMP-9 Negative 18 14 (77.8) 4 (22.2)
 
*Positive ≥ 65 †Negative < 65.
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DISCUSSION
The principal components of adherens junctions in 
epithelial cells are E-cadherin and β-catenin. E-cadherin 
is a calcium-dependent transmembrane receptor that 
interacts homotypically to the E-cadherin of adjacent 
cells and heterotypically to cytoplasmic-binding proteins, 
including β-catenin, to transduce external signals within 
the cell and provide a physical link to the cytoskeleton 
[40]. Loss of epithelial polarity and decreased E-cadherin 
lead to EMT, they have been described to promote 
invasion and are related to poor prognosis and high-
grade EC tumors [41]. In addition, the upregulation of the 
ETV5 Ets transcription factor has been linked to EMT and 
associated with myometrial infiltration in EC [42]. Our 
previous in vitro and in vivo studies evidenced that ETV5 
promotes EMT by modulation of ZEB1 expression and 
consequent E-cadherin repression, leading to a complete 
reorganization of cell-cell and cell-substrate contacts and 
in the acquisition of migratory and invasive capabilities 
[33, 34]. Moreover, ETV5 has been shown to co-localize 
with MMP-2 and -9 at the invasive front of the tumor [42]. 
The high expression of both metalloproteinase and COX-
2, another direct target of ETV5, has been correlated to 
poor prognosis and relapse in EC [43, 44].
A critical role has been evidenced in the process 
of EMT and E-cadherin expression downregulation, by 
SNAIL-related zinc-finger transcription factors (SNAIL 
and SLUG). The overexpression of SNAIL and SLUG has 
been seen closely associated with the reduced expression 
of E-cadherin in EC, and particularly at the invasive 
front of the tumor [45, 46]. Specifically, SNAIL nuclear 
immunoexpression has been described to take place 
concomitantly with a decrease in E-cadherin expression at 
the invasive front of stage IB EEC [45].
In this study, we used an extracellular-ALCAM 
antibody to assess the non-cleaved protein expression by 
immunohistochemistry in two different tumor areas from 
116 EEC primary tumors, i.e. at the superficial and the 
invasive front. Then, its expression was related to a set 
of epithelial (E-cadherin, β-catenin) and mesenchymal 
(ETV5, COX-2, MMP-2, MMP-9, SNAIL, and SLUG) 
EEC relevant markers. While at the superficial tumor, 
uncleaved ALCAM maintained a correlation with 
the major adhesion complex E-Cadherin/β-catenin; 
at the invasive tumor, where a more mesenchymal 
microenvironment takes place, it correlated with COX-
2, SNAIL, MMP-9 and ETV5 mesenchymal markers. 
Interestingly, in the moderately-poorly differentiated 
tumors E-cadherin and ALCAM were positively correlated 
at the superficial area, whilst ETV5 and MMP-9 presented 
a significant negative correlation with extracellular 
ALCAM at the invasive front. Moreover, we evidenced 
that the correlation between ALCAM and MMP-9 was 
only significant in poor prognostic scenarios, i.e. in 
moderately-poorly differentiated tumors, in patients 
presenting myometrial invasion >50%, and ETV5-
positive tumors. Furthermore, at the invasive front, we 
demonstrated that ALCAM-negativity was an independent 
prognostic marker of myometrial invasion together with 
the tumor grade.
ALCAM-negativity was directly associated to an 
increased shedding of the protein, as demonstrated by 
the increased expression of sALCAM in uterine aspirates 
from patients with moderately-poorly differentiated EEC 
presenting myometrial invasion >50%. In our study, 
ROC analysis corroborated sALCAM as a significant 
predictor of myometrial invasion (AUC=0.80). These 
findings are particularly interesting as uterine aspirates 
are the preferable biopsy used in EC diagnosis and the 
assessment of sALCAM might open the avenue to 
develop a potential tool to determine pre-operatively the 
myometrial infiltration (sensitivity 87.0%, specificity 
70.6%) at the time of diagnosis, even in earlier EC stages 
[47]. In addition, sALCAM and MMP-9 were significantly 
strongly correlated in the same patients presenting 
myometrial invasion >50%. Actually, sALCAM has been 
detected in FFPE [22] and in several biofluids [31, 48, 49], 
and related to tumor progression and poor patient outcome. 
Disruption of ALCAM–ALCAM interactions between 
cells promotes tumor cell motility and metastasis, then 
shedding may predict tumor progression at a molecular 
level. In fact, ectopic expression of mutant ΔN-ALCAM 
in melanoma cells induced loss of cellular aggregation, 
increased motility in skin reconstructs and lung metastasis 
formation at the expense of primary tumor [50].
In vivo and in vitro ETV5-overexpressing models 
of EEC were selected. Only in the ETV5-overexpressing 
invading tumors, uncleaved ALCAM was decreased at the 
invasive front, concomitant with an increase in MMP-9 
expression. MMP-9 expression has been associated with 
increased metastatic potential in many cancer types [51]. 
Its activity modulates cell-cell and cell-matrix attachment 
and has been described to regulate the cell invasion and 
migration processes. Here, we could hypothesize that 
MMP-9 is responsible of ALCAM shedding, in invasive 
scenarios.
Moreover, we proved that ALCAM-recovery in 
ETV5-overexpressing cells decreased migration, increased 
cell-cell adhesion, and presented a more collective pattern 
of spreading. In addition, we evidenced that a larger 
adhesion force was necessary to separate the full-length 
ALCAM-transfected cell doublet, indicating its capacity 
to promote intercellular adhesion strengthening and 
manifesting the crucial role of its cytoplasmic tail in the 
maturations of cell-cell adhesion. In fact, the cytoplasmic 
tail of ALCAM has been described to interact with the 
actin cytoskeleton, and could be essential in translation 
of external mechanical forces into the cell to activate 
biochemical signals [50, 52].
These differences in cell-cell adhesion, in the cell 
speed and the pattern of migration could be partially 
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explained by the decrease of the active levels of p-ERK. 
The link between the role of BDNF in the modulation 
of EMT induced by ETV5 and the acquisition of 
cell migratory/invasive capabilities through p-ERK 
phosphorylation has been established [39]. The known 
role of the BDNF–TrkB–ERK1/2 axis on neuronal 
plasticity and organogenesis might be mediating 
pro-metastatic events in endometrial cancer and as 
Figure 2: Soluble ALCAM detected in uterine aspirates is a marker of myometrial invasion and correlates with 
MMP-9. (A) Soluble ALCAM detected by ELISA in uterine aspirates was significantly increased in patients presenting myometrial 
invasion (p-value<0.001). ALCAM values were normalized to total protein amount from the uterine aspirates. (B) ROC curve of sALCAM 
individual marker demonstrated its prognostic value to discriminate patients with myometrial invasion (AUC=0.800; p-value=0.001). 
(C) Two different examples of gelatin zymography from uterine aspirates and detection of the different forms of MMP-9 and MMP-2. 
(D) Principal component analysis from the MMP-9 detected molecular forms evidenced two principal components: C1 (75.18% of the 
variability) and C2 (13.86% of the variability). The factor loadings, correlation between the original variables and the C1 component, 
of each form can be observed in the graph. The KMO obtained was 0.80 and the t Barlett <0.001. (E) The principal component C1 and 
the sALCAM were significantly correlated in all patients (R=0.447; p-value=0.004). (F) The correlation between the C1 component and 
sALCAM was significant in patients with myometrial invasion >50% (R=0.575; p-value=0.004).
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consequence the decrease in the p-ERK levels would 
lead to a less aggressive phenotype [39]. Moreover, some 
authors evidenced that sustained MAPK activation could 
lead to enhanced induction of proteolytic enzymes in the 
surrounding environment in tumors and specifically, the 
inhibition of ERK activation by MEK inhibitor PD098059 
Figure 3: ALCAM is decreased at the invasive front of primary tumors of a controlled model of EEC dissemination. 
(A) Upper: Immunohistochemistry of ETV5, ALCAM and MMP-9 in Hec1A control mice. ALCAM and MMP-9 presented a homogeneous 
staining between the superficial and invasive front or disseminated cells. Black arrow signals a cluster of disseminated cells released 
from the primary tumor. Down: Immunohistochemistry of ETV5, ALCAM and MMP-9 in Hec1A-ETV5 mice. ALCAM expression was 
decreased at the invasive front of the tumor, concomitant with an increase of MMP-9 expression. Black arrows evidenced disseminated cells 
in finger-strand or individual cells, released from the ETV5-overexpressed primary tumor. (B) Representation of the intensity of staining 
of ALCAM and MMP-9. Only, ALCAM expression was significantly decreased at the invasive front of the ETV5-overexpressing mice, 
compared to control (*p<0.05). (C) Relative intensity of ALCAM and MMP-9 markers at the invasive front compared to the superficial 
tumor. While in the control mice, both markers where homogeneous across the section, in the ETV5-overexpressing mice we observed a 
decreased in ALCAM expression concomitant with an increase in MMP-9 expression in the invasive front of the primary tumors.
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has been described to partially block MMP-9 production 
and attenuate the in vivo invasiveness of head and neck 
squamous cancer cells [53].
Although further research is needed to define 
the exact mechanisms, in vitro and in vivo models 
evidenced that ALCAM participates in cell-cell adhesion 
and collective cell migration, and suggested that to 
allow invasion in the frontier between tissues-restricted 
carcinoma and disseminated tumor cells, a dynamic 
and adaptive switch between ALCAM expression at 
the cell surface and cleaved ALCAM by MMP-9 might 
take place. In fact, cancer cell invasion is currently 
viewed as a heterogeneous and adaptive process [54] 
in which, the plasticity in cell adhesion, the dynamics 
of the cytoskeleton and the mechanotransduction of 
external stimuli are key processes. Taking into account 
that myometrial invasion is highly associated with poor 
prognosis and to a limited therapeutic response, our 
Figure 4: ALCAM overexpression in mesenchymal Hec1A-ETV5 cells decreased cell migration and enhanced cell-
cell adhesion. (A) Representation of the two vectors constructed to overexpress ALCAM: full-length ALCAM and ALCAMcytoless 
inserted in the pmCherry-N1 construct. (B) Images of the Hec1A-ETV5 cell line transfected with the pmCherry vector as a control, and 
both ALCAM-overexpression constructs. (C) Western-blot analysis evidenced that ALCAM-Cherry was predominantly expressed in the 
cell membrane in Hec1A-ETV5 cells. (D) Images of the 3D spheroid-spreading model are illustrated at different time points. In the control 
cells, the spheroids were almost disaggregated after 5 h, whilst the mean time for disaggregation for the ALCAMcytoless cells was around 
18 h, and more than 21 h for the full-length ALCAM cells. (E) Effect of ALCAM overexpression on migration was assessed by a 3D 
spheroid-spreading model on 200 μm fibronectin-coated stripes. On the left, box plot of the speed of migration for each cell line. On the 
right, representative images at time 0 h and at 24 h are illustrated and the spreading reached at 24 h is outlined in the images. Migration 
decreased in cells transfected with full-length ALCAM (**p<0.01) and ALCAMcytoless (*p<0.05) compared to control (m/s, meter/second) 
(F) Left: Two Cherry transiently transfected cells were put into contact and allowed to form adhesion. After 4 and 10 min, we applied an 
increasing measurable force (nN) up to the disruption of the formed cell doublet. Right: Full-length ALCAM-overexpression increased 
cell-cell adhesion at all points, as shown by quantification of the separation force (***p<0.001). However, ALCAMcytoless only increased 
cell-cell adhesion at 4 min and showed no differences with control line at 10 min. (G) Western-blot analysis of ALCAM-overexpression in 
Hec1A-ETV5 cells demonstrated a significant decrease in the levels of ERK-phosphorylation.
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research opens an avenue for the use of ALCAM-recovery 
as a therapeutic approach to control tumor invasion.
MATERIALS AND METHODS
Human endometrial cancer samples
Formalin-fixed paraffin-embedded tissue samples 
from 116 EEC patients were recruited from the Hospital 
del Mar (Barcelona, Spain). For each patient, we selected 
4 macroscopically differentiated areas: 2 superficial, 
which were obtained from the core of tumor; and 2 
invasive, which were obtained from the tumor in contact 
with the invasive front.
Forty uterine aspirates, from EEC patients were 
collected prior to surgery by aspiration in the Vall Hebron 
University Hospital (Barcelona, Spain), with a Cornier 
Pipelle (Eurogine Ref. 03040200). PBS1x was added (1:1) 
and centrifuged 20 min at 2,500 rcf to separate the soluble 
fraction.
All samples were obtained after the approval 
of the ethical committee of each institution. The 
clinicopathologic characteristics of all patients are detailed 
in Supplementary Table 4.
Immunohistochemical staining
Tissue microarray and immunohistochemistry 
were performed as previously described [34]. ALCAM, 
E-cadherin, β-catenin, ETV5, COX-2, MMP-2, MMP-9, 
SLUG, and SNAIL immunohistochemical expressions 
were analyzed in both areas of the tumor (superficial and 
invasive). Immunohistochemical staining for ALCAM 
was conducted with MOG/07 antibody (ab49496; Abcam, 
Cambridge, MA, USA) directed against the extracellular 
domain of the protein. Specifically, the antibody is 
raised against a 200-amino-acid-long peptide from the 
extracellular region of ALCAM, detecting the full-
ALCAM or non-cleaved protein. Antigen retrieval and 
primary antibody incubation were performed as previously 
described [32]. To detect MMP-2, MMP-9, and ETV5, 
citrate buffer pH 9 was used for antigen retrieval. Then 
the sections were incubated with 1:100 rAb ETV5 (H-100; 
Santa Cruz Biotechnology, CA, USA), 1:50 mAb MMP-
2 (CA-4001; Abcam, Cambridge, MA, USA), and 1:50 
rAb MMP-9 (3852; Cell Signaling Technology, Beverly, 
MA, USA) for 1h or 2h (ETV5) at room temperature. 
Detection of COX-2, SLUG, and SNAIL was performed 
with antigen retrieval citrate pH 6 buffer. The sections 
were incubated overnight using 1:100 gAb COX-2 (M-
19; Santa Cruz Biotechnology, CA, USA), 1:250 rAb 
SLUG (ab27568; Abcam), 1:125 gAb SNAIL (ab53519; 
Abcam) for 1h at room temperature. Primary antibodies 
mAb E-cadherin and mAb β-Catenin (36 and 14; Roche, 
Basel, Switzerland) were used with Ventana Benchmark 
automated slide stainer, 24 min at 36°C.
A pathologist evaluated the expression of each 
protein using immunoreactive scores (IRS). ALCAM, 
E-Cadherin, SNAIL, SLUG, and COX-2 expressions 
were evaluated from the product of the staining intensity 
(ranging from 1-3) and the percentage [0-100%] of 
neoplastic cells with positive staining. The product of the 
two assessments yielded final values on a scale ranging 
from [0–300]. ETV5, β-catenin, MMP-2 and MMP-9 were 
only evaluated based on the percentage, in scale IRS [0-
100%]. For the selected candidates (ALCAM, ETV5 and 
MMP-9), the IRS was dichotomized (positive/negative), 
by using the average of their staining (obtained from the 
superficial and the invasive staining) and the cut-off values 
were established with the first quartile of its distribution, 
in each case. The cut-off for each protein was: ALCAM 
positive ≥ 65, ETV5 positive ≥ 25, MMP-9 positive >5.
Soluble ALCAM detection in uterine aspirates
The ALCAM Duoset ELISA kit (R&D Systems, 
Minneapolis, USA) was used to detect ALCAM levels 
in the supernatant of the uterine aspirates according to 
manufacturers’ instructions. All samples were diluted 
1:100 in BSA 1%.
Zymography
Proteins with metalloproteinase activity were 
identified by gelatin zymography and equal quantities of 
protein, from the uterine aspirates, were size fractionated 
as previously described [35].
Cell lines, constructs and transient cell lines 
generation
The human Hec1A and the Hec1A-ETV5 EEC 
cells were generated and maintained as described in 
Monge et al. [35]. To monitor non-invasively tumor 
grafts of Hec1A and Hec1A-ETV5 cell lines, cells 
were infected with lentiviruses bearing pLenti CMV 
V5-LUC Blast (w567-1) (Addgene, Cambridge, MA, 
USA) to constitutively express the luciferase reporter 
gene, as previously described [55]. For transient 
ALCAM-overexpression in Hec1A-ETV5, we amplified 
ALCAM full-length and ALCAM extracellular-
transmembrane domains, without the cytoplasmic tail 
(ALCAMcytoless), from an EEC tissue, using the 
forward primer 5’-GCAACTCGAGATGGAATCCAA
GGGGGCCA-3’, and 2 reverse primers 5’-GCTTGAA
TTCCGGCTTCAGTTTTGTGATTGTT-3’ and 5’- GC
TTGAATTCGCAGCCAGTAGACGACACCAG-3’, 
respectively. Both amplified regions were inserted in 
pmCherry-N1 vector (Clontech Laboratories, Mountain 
View, CA, USA) with XhoI and EcorI. Transfection 
was performed using Lipofectamine 2000 (Invitrogen) 
following manufacturers’ instructions.
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Orthotopic murine model and bioluminescent 
imaging
All the procedures were performed according to the 
guidelines of the Spanish Council for Animal Care and 
the institutional guidelines for animal welfare (CEEA 
23/16). A total of 9 six-week-old female athymic nude 
mice (Charles River Laboratories, Inc, Wilmington, MA) 
were inoculated by transmyometrial injection of Hec1A 
luciferase control cells (n=5) and stably transfected 
Hec1A-ETV5 luciferase cells (n=4) as described in 
[56]. Mice were sacrificed 3 weeks after the injection. 
All extracted tissues were formalin-fixed, stained with 
haematoxylin and eosin, and evaluated by a pathologist. 
After cells injection and before sacrifice, a weekly follow-
up was carried out using the IVIS system (Xenogen 
Corporation) coupled to Living Imaging software 4.2 
(Xenogen Corporation) in order to detect tumor growth 
by bioluminescent imaging. Luciferin (Firefly Luciferin, 
Caliper Lifescience Corp, Hopkinton, MA, USA) was 
used as the substrate for the luciferase expressing tumor 
cells and injected intraperitoneally at a concentration of 
150 mg/kg in PBS.
Western-blot and protein cell extraction
Cell extraction and western-blot were performed 
as previously described [33]. Incubation with primary 
antibodies was performed at 4°C overnight using 1:500 
mAb ALCAM (MOG/07, Abcam, Cambridge, MA, USA); 
1:2000 rAb a-Tubulin, 1:2000 rAb ERK1/2, 1:1000 rAb 
p-ERK1/2 (Cell Signaling Technology, Beverly, MA, 
USA), 1:2500 rAb Lamin (Santa Cruz, CA, USA), 
1:5000 rAb mCherry ([57]; an aliquot of the antibody 
was kindly provided by Drs. Anna Santamaría and Erich 
A. Nigg). Nuclear, membrane and cytosolic fractionation 
of transfected Hec1A-ETV5 cells was performed by 
using a Subcellular Fractionation Kit (Pierce) as per the 
manufacturer’s instructions.
Measurement of the separation force between cells
Forces were measured on the stage of an inverted 
epifluorescence microscope (Leica) equipped with 
objectives of 63x (PL FLUOTAR; NA/0.7; C PLAN 
NA/0.75) and with a cooled CCD C5985 (Hamamatsu) 
or Coolpix 5000 camera (Nikon) as previously described 
[58]. To preserve intact the cell surface proteins, cells 
were dissociated with Cell dissociation enzyme-free 
buffer (Gibco, NY, USA) and then transferred in working 
medium (CO2-independent medium, Invitrogen, CA, 
USA) and used immediately. Two isolated cells were 
put into contact and allow forming adhesion for specific 
period times. Aspiration was monitored continuously by 
a pressure sensor (model DP103-38; Validyne) during 
the separation process and the values recorded for each 
of the last two cycles in the series (Pn-1 and Pn) were 
used to calculate the separation force (SF) for each doublet 
using the equation: SF = π (d/2)2 (Pn-1+Pn)/2 where d 
is the inside diameter of the left pipette. Results for 15–
30 measurements were used to obtain the mean SF for a 
specific contact time.
Aggregate spreading
Aggregates were obtained from 5 mL of cell 
suspension in CO2-equilibrated culture medium at a 
concentration of 4 × 105 cells per milliliters in 25 mL 
Erlenmeyer flasks and placed in a gyratory orbital shaker 
at 75 rpm at 37°C for 22 h. The flasks were pretreated 
with 2% dimethylchlorosilane in chloroform to prevent 
adhesion of cells to the glass surface.
For the preparation of coated glass substrates: twenty-
five millimeter circular glass coverslips were sonicated 
in ethanol for 5 min, dried at ambient temperature, and 
exposed to deep UV for 5 min. Fibronectin (Sigma-Aldrich, 
Missouri, USA) coating was performed using a 0.1 mg/
mL solution of fibronectin in PBS solution (pH 7.4) for 1 
h. Mixed coating of fibronectin and PEG-PLL (PLL(20)-
g[3.5]-PEG(2), Surface Solution) was done by mixing at 
various rates a 0.1 mg/mL fibronectin in phosphate buffer 
solution (PBS; pH 7.4) and a 0.1 mg/mL PEG-PLL in Hepes 
solution (pH 7.3) for 1 h. Coverslips were then rinsed with 
PBS (pH 7.4).
As previously described [59], aggregates were 
deposited randomly on striped fibronectin-coated 
coverslips in a magnetic imaging chamber (Chamlide 
CMB, CM-B25-1) filled with CO2-equilibrated culture 
medium. Spreading was observed using a NIKON 
confocal microscope with an x10 air objective and a 37°C 
heating cube system. Bright field images were recorded 
for 36 h with a CCD camera (Luca-R, Andor) using NIS-
Elements software. The increased spreading was measured 
at different time points with Image J software (National 
Institutes of Health, Bethesda), which allowed calculating 
the speed of migration for each cell line.
Immunofluorescence
After 48 h of transfection, cells seeded onto glass 
coverslips were fixed with 4% paraformaldehyde, blocked 
in PBS-BSA 4% and incubated with DAPI for 15 min at 
RT in dark. Coverslips were mounted using the Aqua/Poly 
Mount medium (Polysciences Europe GmbH, Eppelheim, 
Germany). Fluorescence images were captured with 
Spectral Confocal Microscope FV1000 (Olympus, 
Hamburg, Germany).
Statistical analysis
For continuous variables: univariate and multivariate 
linear regression analyses were performed to evaluate 
the association between ALCAM and epithelial or 
mesenchymal markers at the superficial and the invasive 
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front. For each cohort, a stepwise method was used to 
select the explanatory variables based on analysis of 
variance, checking the normality (Kolmogorov-Smirnov) 
and the independence of residuals (Durbin-Watson).
Receiver operating characteristic (ROC) curve 
analysis was conducted on the individual soluble ALCAM 
(sALCAM) expression detected in uterine aspirates at 
diagnosis, to evaluate the potential of this parameter as 
a marker to discriminate patients presenting myometrial 
infiltration. To explore its relationship with the different 
forms of MMP-9 present in the uterine aspirates, we 
performed a factor analysis with extraction of principal 
component (PCA) and then, a regression analyses with 
sALCAM levels. The normal distribution of the data 
was verified (Kolmogorov-Smirnov) and levels were 
ln-transformed for linear analyses. Non-parametric test 
(Mann Whitney) were used for comparisons of data sets 
whose distributions deviate from normal. Measurements 
were made in triplicates in three independent experiments 
and presented with the Mean±SD (except for the 
separation force experiments, which were presented by 
Mean±SEM).
For categorical variables: the relationships between 
ALCAM expression at the superficial and the invasive 
front and clinicopathological parameters were tested in 
univariate analysis by Chisquare and Fisher’s exact test. 
Stratified analysis was performed to study the molecular 
features ALCAM/MMP-9/ETV5 and the crosstalk 
between ALCAM/MMP-9 and clinicopathological 
parameters. The odds ratios (OR), with their confidence 
interval (IC 95%) were obtained through bootstrapping 
methods. Logistic regression multivariate analysis was 
done for the clinicopathological parameters and the 
biomarkers status to determine independent predictors for 
myometrial infiltration.
All statistical analyses were performed using the 
IBM SPSS Statistics 21. All two-sided p-values < 0.05 
were considered statistically significant.
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